Breast cancer severity score is an innovative system for prognosis

American Journal of Surgery

Volumn 186, Issue 4, 2003, Pages 404-408

  Jimenez Lee, Ricardo ^a   Ham, Bruce ^a   Vetto, John ^a   Pommier, Rodney ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Biologic characteristics; Prognostic tool; Scoring system

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ANALYTIC METHOD; BREAST CANCER; BREAST CANCER SEVERITY SCORE; CANCER PATIENT; CANCER SURVIVAL; DISEASE SEVERITY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL RECORD; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; UNIVERSITY HOSPITAL; ARTICLE; BREAST TUMOR; CHEMISTRY; DISEASE FREE SURVIVAL; FEMALE; HOSPITALIZATION; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 0142213201     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(03)00283-6     Document Type: Article

References (30)

1. Singletary S.E., Allerd C., Ashley P., et al. Revision of the American Committee on Cancer staging system for breast cancer. J Clin Oncol. 17:2002;3628-3636.
2. Daly JM, Bertagnolli M, DeCosse JJ, Morton DL. Oncology. In: Schwartz SI, Shires GT, Spencer FC, et al, eds. Principles of surgery. 7th ed. New York: McGraw Hill, p 303.
3. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
4. Beahrs OH, Henson DE, Hutter RVP, et al, editors. American Joint Committee on Cancer. Manual for staging of breast cancer. 4th ed. 1992, p 145-50.
5. Haagenson C.D., Stout A.P. Carcinoma of the breast criteria for operability. Ann Surg. 118:1943;859-870.
6. Hermanek P, Sobin LH, editors. UICC TNM classification of malignant tumors. 4th ed. 1987, p 94-9.
7. Lee B.J., Stubenbord J.G. Clinical index for carcinoma of the breast. Surg Gynecol Obstet. 47:1928;812-814.
8. Patterson R. The treatment of malignant disease by radium and x-rays. 1948;Edward Arnold, London.
9. Portmann U.V. Clinical and pathologic criteria as a basis for classifying cases of primary cancer of the breast. Cleveland Clin Q. 10:1943;41-47.
10. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 63:1989;181-187.
11. Veronesi U., Galimberti V., Zurrida S., et al. Prognostic significance of number and level of axillary node metastasis in breast cancer. Breast. 2:1993;224-228.
12. Fisher E.R., Sass R., Fisher B., et al. Pathologic findings from the National Surgical Adjuvant Project for breast cancer (protocol no. 4). Discrimination for tenth year treatment failure. Cancer. 53:1984;712-723.
13. Koscielny S., Tubiana M., Le M.G., et al. Breast cancer relationship between the size of the primary tumor and the probability of metastatic dissemination. Br J Cancer. 49:1984;709-715.
14. Henderson I.C., Canellos G.P. Cancer of the breast the past decade. N Engl J Med. 302:1980;17-30.
15. Fisher E.R. Prognostic and therapeutic significance of pathological features of breast cancer. Natl Cancer Inst Monogr. 1:1986;29-34.
16. Crowe J.P., Gordon N.H., Huban C.A., et al. Estrogen receptor determination and long-term survival of patients with carcinoma of the breast. Surg Gynecol Obstet. 173:1991;273-278.
17. Fisher B., Redmond C., Fisher E.R., et al. Relative worth of estrogen and progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients findings from National Surgical Adjuvant Breast and Bowel Project protocol B-06. J Clin Oncol. 6:1988;1076-1087.
18. Kato T, Kameoka S, Kimura T, et al. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer. Anticancer Res R 2002;22:1097-103.
19. Galea M.H., Blamey R.W., Elston C.W., et al. The Nottingham prognostic index in primary breast cancer. Br Cancer Res Treat. 22:1992;207-219.
20. Rampaul R.S., Pinder S.E., Elston C.W., Ellis I.O. Prognostic and predictive factors in primary breast cancer and their role in patient management the Nottingham Breast Team. EJSO. 27:2001;229-238.
21. Silverstein M.J., Poller D.N., Waisman J.R. Prognostic classification of breast ductal carcinoma in situ. Lancet. 345:1995;1154-1157.
22. Silverstein M.J., Lagios M.D., Craig P.H., et al. The Van Nuys prognostic index for ductal carinoma in situ. Breast J. 2:1996;38-40.
23. Silverstein M.J., Poller D.N., Craig P.H., et al. A prognostic index for breast ductal carcinoma in situ. Breast Cancer Res Treat. 37:1997;34.
24. Silverstein M.J., Poller D.N., Craig P.H., et al. A prognostic index for ductal carinoma in situ of the breast. Cancer. 77:1996;2267-2274.
25. Frank I., Blute M.L., Cheville J.C., et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis The SSIGN score. J Urol. 168:2002;2395-2400.
26. Kern K. Causes of breast cancer malpractice litigation. Arch Surg. 127:1992;542-547.
27. Dennis C.R., Gardner B., Lim B. Analysis of survival and recurrence vs. patient and doctor delay in treatment of breast cancer. Cancer. 35:1975;714-720.
28. Polychemotherapy for early breast cancer: an overview of the randomized trials: Lancet 1998;352:930-42.
29. van de Vijer M.J., He Y.D., van't Veer L., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347:2002;1999-2009.
30. Keyomarsi K., Tucker S.L., Buchholz T.A., et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 347:2002;1566-1575.